Drug reference

panobinostat

pan-HDAC inhibitor · Antineoplastic agent

pan-HDAC inhibitorAntineoplastic agent

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

FDA category + note

Top interactionssee all 12 →

AbarelixSevereDatabaseDDInter
AbciximabSevereDatabaseDDInter
AbirateroneSevereDatabaseDDInter
AcalabrutinibSevereDatabaseDDInter

Mechanism

Panobinostat is an orally bioavailable, nonselective pan-HDAC inhibitor. The inhibitory activity leads to apoptosis of malignant cells via multiple pathways. Inhibition of HDAC activity causes the accumulation of acetyl groups on histone lysine residues, an open chromatin structure, and activation of target genes that are selectively repressed in tumors.

Indications

MM who have received at least two previous treatments, including bortezomib and an immunomodulatory agentRelapsed multiple myeloma

Pharmacokinetics

Half-life

approximately 37 h (elimination)

Bioavailability

about 21% (oral)

Metabolism

CYP3A

Side effects

Common

diarrhea (severe in 25% of patients)fatiguenauseaperipheral edemadecreased appetitepyrexiavomitinghypophosphatemiahypokalemiahyponatremiaincreased creatininethrombocytopenialymphopenialeukopeniaanemia

Serious

fatal cardiac ischemic events
severe arrhythmias
ECG changes

Pregnancy & lactation

Pregnancy